RMC-6291 is a small molecule commercialized by Revolution Medicines, with a leading Phase II program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 3 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of RMC-6291’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for RMC-6291 is expected to reach an annual total of $48 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

RMC-6291 Overview

RMC-6291 is under development for the treatment of solid tumor, non-small cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma. The drug candidate is a second-generation, tri-complex inhibitors. It is administered through oral route. It acts by targeting the GTP bound form of KRAS (G12C) and NRAS (G12C).

Revolution Medicines Overview

Revolution Medicines is a clinical-stage precision oncology company that discover and developed medicines and therapies for cancer patients. The company product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2, a central node in the RAS signaling pathway. Its other product includes RMC-4630, RMC-5552, SOS1. Revolution Medicines also provide a research and development pipeline comprising RAS(ON) inhibitors that bind directly to RAS variants. The company partners with pharmaceutical companies and healthcare organizations for its drug development activities. Revolution Medicines is headquartered in Redwood City, California, the US
The company reported revenues of (US Dollars) US$11.6 million for the fiscal year ended December 2023 (FY2023), a decrease of 67.3% over FY2022. The operating loss of the company was US$487.2 million in FY2023, compared to an operating loss of US$258.3 million in FY2022. The net loss of the company was US$436.4 million in FY2023, compared to a net loss of US$248.7 million in FY2022.

For a complete picture of RMC-6291’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.